6,039 results match your criteria Blood Dyscrasias and Stroke


Early-onset cardiac dysfunction following allogeneic haematopoietic stem cell transplantation.

Open Heart 2022 May;9(1)

Department of Haematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.

Objective: Heart failure following allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a serious complication that requires early detection; however, the clinical implications of early-onset cancer therapy-related cardiac dysfunction (CTRCD) following allo-HSCT remain unclear. We investigated the determinants and prognostic impact of early-onset CTRCD in allo-HSCT recipients.

Methods: The records of 136 patients with haematological malignancies who underwent allo-HSCT at our institute were retrospectively reviewed. Read More

View Article and Full-Text PDF

Deficiency of Human Adenosine Deaminase Type 2 - A Diagnostic Conundrum for the Hematologist.

Front Immunol 2022 3;13:869570. Epub 2022 May 3.

Pediatric Allergy Immunology Unit, Department of Pediatrics, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

Deficiency of adenosine deaminase type 2 (DADA2) was first described in 2014 as a monogenic cause of polyartertitis nodosa (PAN), early onset lacunar stroke and livedo reticularis. The clinical phenotype of DADA2 is, however, very broad and may involve several organ systems. Apart from vasculitis, children may present with i) Hematological manifestations (ii) Lymphoproliferation and iii) Immunodeficiencies. Read More

View Article and Full-Text PDF

Stroke in sickle cell disease in association with bilateral absence of the internal carotid arteries. Case report.

BMC Neurol 2022 May 17;22(1):182. Epub 2022 May 17.

Child Health Department, Sultan Qaboos University Hospital, Muscat, Oman.

Background: Congenital absence of the internal carotid artery (ICA) is a highly infrequent congenital incidence and occurs in less than 0.01% of the population; bilateral absence is exceedingly rare, diagnosed below 10% of the unilateral absence of the ICA. Sickle cell disease (SCD) is a serious disorder and carries a high risk of stroke. Read More

View Article and Full-Text PDF

Anemia warrants treatment to improve survival in patients with heart failure receiving sacubitril-valsartan.

Sci Rep 2022 May 17;12(1):8186. Epub 2022 May 17.

School of Pharmacy, College of Medicine, National Taiwan University, R201, No. 33, Linsen S. Rd., Zhongzheng Dist., Taipei, 100, Taiwan.

Angiotensin inhibition remains a cornerstone for pharmacologic management of heart failure (HF), despite being associated with decreased hemoglobin (Hb) levels. To investigate the effect of anemia and its treatment on patients with HF treated with sacubitril-valsartan (S/V), we conducted a retrospective study involving patients with recorded left ventricular ejection fractions (LVEFs) of < 40% between January 2017 and December 2019. We identified 677 patients, 37. Read More

View Article and Full-Text PDF

Cerebral Cavernous Malformation Pathogenesis: Investigating Lesion Formation and Progression with Animal Models.

Int J Mol Sci 2022 Apr 30;23(9). Epub 2022 Apr 30.

Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.

Cerebral cavernous malformation (CCM) is a cerebromicrovascular disease that affects up to 0.5% of the population. Vessel dilation, decreased endothelial cell-cell contact, and loss of junctional complexes lead to loss of brain endothelial barrier integrity and hemorrhagic lesion formation. Read More

View Article and Full-Text PDF

Single-cell transcriptional profiling of human carotid plaques reveals a subpopulation of endothelial cells associated with stroke incidences.

J Cell Mol Med 2022 May 8. Epub 2022 May 8.

Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, Suzhou Key Laboratory of thrombosis and vascular diseases, Soochow University, Suzhou, China.

The differences in plaque histology between symptomatic and asymptomatic patients have been widely accepted. Whether there is a heterogeneity of cells between symptomatic and asymptomatic plaques remains largely unclear. To reveal the potential heterogeneity within different plaques, which may contribute to different stroke incidences, we obtained the scRNA-seq data from symptomatic and asymptomatic patients and identified eight cell types present in plaques. Read More

View Article and Full-Text PDF

Anemia and iron deficiency in patients with atrial fibrillation.

BMC Cardiovasc Disord 2022 05 4;22(1):204. Epub 2022 May 4.

Centre for Heart Rhythm Disorders, University of Adelaide, Adelaide, Australia.

Atrial fibrillation (AF) is the most common cardiac tachyarrhythmia and has a rising global prevalence. Given the increasing burden of AF-related symptoms and complications, new approaches to management are required. Anemia and iron deficiency are common conditions in patients with AF. Read More

View Article and Full-Text PDF

Medical Management of a Mural Thrombus Inducing Repeated Ischemic Strokes in a Patient with Congenital Afibrinogenemia.

J Stroke Cerebrovasc Dis 2022 Jul 27;31(7):106526. Epub 2022 Apr 27.

Department of Neurosurgery, Nagoya University of Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, Japan.

Objectives: Congenital afibrinogenemia is an autosomal recessive inherited disorder that can cause thrombotic as well as hemorrhagic events. We describe a case of repeated mild ischemic strokes due to a mural thrombus in the carotid artery and our medical treatment.

Case Description: A 49-year-old woman with congenital afibrinogenemia developed two minor ischemic strokes in two months. Read More

View Article and Full-Text PDF

Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic.

Vaccine 2022 May 18;40(23):3150-3158. Epub 2022 Apr 18.

Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States.

Background: The COVID-19 pandemic caused an abrupt drop in in-person health care (inpatient, Emergency Department, outpatient) and an increase in telehealth care, which poses challenges in vaccine safety studies that identify outcomes from in-person encounters. We examined the changes in incidence rates of selected encounter-based outcomes during the COVID-19 pandemic.

Methods: We assembled a cohort of members from 8 Vaccine Safety Datalink sites from January 1, 2017 through December 31, 2020. Read More

View Article and Full-Text PDF

Thromboelastography maximum amplitude as an early predictor of disseminated intravascular coagulation in patients with heatstroke.

Int J Hyperthermia 2022 ;39(1):605-610

Department of Critical Care Medicine, the 908th Hospital of Chinese Logistical Support Force, Nanchang, China.

Objectives: The aim of this study was to investigate the ability of TEG to predict DIC associated with heatstroke.

Methods: We carried out a retrospective, single-center study of 67 patients with heatstroke admitted to an intensive care unit (ICU) at a comprehensive hospital between July 2016 and August 2021. Conventional coagulation tests (CCTs) and TEG were performed within 2 h of admission in ICU. Read More

View Article and Full-Text PDF

Long-term effects of baseline on-treatment platelet reactivity in patients with acute coronary syndrome and thrombocytopenia undergoing percutaneous coronary intervention.

J Int Med Res 2022 Apr;50(4):3000605221081725

Department of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China.

Objective: To analyse the association between on-treatment platelet reactivity (TPR) and long-term outcomes of patients with acute coronary syndrome (ACS) and thrombocytopenia (TP) in the real world.

Methods: This prospective observational study enrolled patients with coronary artery disease (CAD) that underwent percutaneous coronary intervention (PCI). Patients with ACS and TP under dual antiplatelet therapy were selected for analysis. Read More

View Article and Full-Text PDF

Impaired coagulation, liver dysfunction and COVID-19: Discovering an intriguing relationship.

World J Gastroenterol 2022 Mar;28(11):1102-1112

"Clinica Medica" Institute, Department of Medicine and Aging Sciences, "G. D'Annunzio" University of Chieti-Pescara, Chieti 66100, Italy.

Coronavirus disease 2019 (COVID-19) is, at present, one of the most relevant global health problems. In the literature hepatic alterations have been described in COVID-19 patients, and they are mainly represented by worsening of underlying chronic liver disease leading to hepatic decompensation and liver failure with higher mortality. Several potential mechanisms used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to cause liver damage have been hypothesized. Read More

View Article and Full-Text PDF

Cerebrovascular Complications of COVID-19 and COVID-19 Vaccination.

Circ Res 2022 Apr 14;130(8):1187-1203. Epub 2022 Apr 14.

Clinical and Translational Neuroscience Unit, Department of Neurology, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY (J.K., A.E.M.).

The risk of stroke and cerebrovascular disease complicating infection with SARS-CoV-2 has been extensively reported since the onset of the pandemic. The striking efforts of many scientists in cooperation with regulators and governments worldwide have rapidly brought the development of a large landscape of vaccines against SARS-CoV-2. The novel DNA and mRNA vaccines have offered great flexibility in terms of antigen production and led to an unprecedented rapidity in effective and safe vaccine production. Read More

View Article and Full-Text PDF

Novel contact-kinin inhibitor sylvestin targets thromboinflammation and ameliorates ischemic stroke.

Cell Mol Life Sci 2022 Apr 13;79(5):240. Epub 2022 Apr 13.

Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Kunming Institute of Zoology, Kunming, Yunnan, 650107, China.

Ischemic stroke is a leading cause of death and disability worldwide. Increasing evidence indicates that ischemic stroke is a thromboinflammatory disease in which the contact-kinin pathway has a central role by activating pro-coagulant and pro-inflammatory processes. The blocking of distinct members of the contact-kinin pathway is a promising strategy to control ischemic stroke. Read More

View Article and Full-Text PDF

[Cerebral venous sinus thrombosis : An overview of causes, diagnostics and treatment].

Nervenarzt 2022 Apr 12;93(4):413-421. Epub 2022 Apr 12.

Neurologische Klinik, Universitätsklinik der RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Deutschland.

In some cases, cerebral venous sinus thrombosis shows a fulminant progress but with an incidence of 1.32 cases per 100,000 person-years it is relatively rare. Nevertheless, the disease is responsible for around 0. Read More

View Article and Full-Text PDF

Strategies to increase access to basic sickle cell disease care in low- and middle-income countries.

Expert Rev Hematol 2022 Apr 12;15(4):333-344. Epub 2022 Apr 12.

Department of Global Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Introduction: Sickle cell disease (SCD) is the most common hemoglobinopathy in the world. Over 90% of those born with SCD live in low- and middle-income countries (LMICs), yet individuals in these settings have much poorer outcomes compared to those in high-income countries.

Areas Covered: This manuscript provides an in-depth review of the cornerstones of basic SCD care, the barriers to implementing these in LMICs, and strategies to increase access in these regions. Read More

View Article and Full-Text PDF

Transplantation of umbilical cord blood-derived mesenchymal stem cells as therapy for adriamycin induced-cardiomyopathy.

Bioengineered 2022 Apr;13(4):9564-9574

Department of Hematologic Oncology, Dalian Municipal Women and Children's Medical Center, Dalian, Liaoning, China.

Umbilical cord blood-derived mesenchymal stem cells (UCBMSCs) have been reported to possess cardioprotective effects in diseases. However, its effects on cardiomyopathy remain unclear. This study aimed to the therapeutic effects of UCBMSC transplantation on adriamycin (ADR)-induced cardiomyopathy. Read More

View Article and Full-Text PDF

[Adenosine deaminase 2 deficiency: a disease with multiple presentations].

Rev Med Suisse 2022 Apr;18(776):669-673

Unité d'immunologie, allergologie et rhumatologie pédiatrique, Service de pédiatrie, Département femme-mère-enfant, Centre hospitalier universitaire vaudois, 1011 Lausanne.

Adenosine deaminase 2 deficiency (DADA2) is a genetic auto- inflammatory disease that most often presents in childhood, but that can also have a late onset in adulthood. It is characterized by vasculitis, mainly of the skin and nervous system most often in the form of a stroke, associated to immunodeficiency and cytopenias. The diagnosis is made by measuring adenosine deaminase 2 (ADA2) enzymatic activity and confirming the presence of mutations in the ADA2 gene by genetic testing. Read More

View Article and Full-Text PDF

Stroke in Hemodialysis Patients Randomized to Different Intravenous Iron Strategies: A Prespecified Analysis from the PIVOTAL Trial.

Kidney360 2021 Nov 16;2(11):1761-1769. Epub 2021 Sep 16.

Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom.

Background: People with kidney failure treated with hemodialysis (HD) are at increased risk of stroke compared with similarly aged people with normal kidney function. One concern is that treatment of renal anemia might increase stroke risk. We studied risk factors for stroke in a prespecified secondary analysis of a randomized, controlled trial of intravenous iron treatment strategies in HD. Read More

View Article and Full-Text PDF
November 2021

Untangling the Association between Anemia Treatment and Stroke Risk in CKD.

Authors:
Jay B Wish

Kidney360 2021 Nov 25;2(11):1693-1695. Epub 2021 Nov 25.

Division of Nephrology, Indiana University Health University Hospital, Indiana University School of Medicine, Indianapolis, Indiana.

View Article and Full-Text PDF
November 2021

Association of Blood Pressure Genetic Risk Score with Cardiovascular Disease and CKD Progression: Findings from the CRIC Study.

Kidney360 2021 Aug 8;2(8):1251-1260. Epub 2021 Apr 8.

Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.

Background: In the general population, genetic risk for high BP has been associated with cardiovascular disease, but not kidney function or incident CKD. These relationships have not been studied longitudinally in participants with CKD. We examined whether BP genetic risk predicts cardiovascular disease and kidney disease progression in patients with CKD. Read More

View Article and Full-Text PDF

Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF).

Biomed Pharmacother 2022 May 1;149:112894. Epub 2022 Apr 1.

Children's Center, the Affiliated Taian City Centeral Hospital of Qingdao University, Taian, Shandong, 271000, PR China. Electronic address:

In recent years, with improvements in treatments for heart failure (HF), the survival period of patients has been extended. However, the emergence of some patients with repeated hospitalizations due to their worsening conditions and low survival rates followed. Currently, few drugs are available for such patients. Read More

View Article and Full-Text PDF

Thromboinflammation in Brain Ischemia: Recent Updates and Future Perspectives.

Stroke 2022 May 1;53(5):1487-1499. Epub 2022 Apr 1.

Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, Germany (F.L., S.H., C.K., A.I.C.).

Despite decades of promising preclinical validation and clinical translation, ischemic stroke still remains as one of the leading causes of death and disability worldwide. Within its complex pathophysiological signatures, thrombosis and inflammation, that is, thromboinflammation, are highly interconnected processes leading to cerebral vessel occlusion, inflammatory responses, and severe neuronal damage following the ischemic event. Hence, we here review the most recent updates on thromboinflammatory-dependent mediators relevant after stroke focusing on recent discoveries on platelet modulation, a potential regulation of the innate and adaptive immune system in thromboinflammation, utterly providing a thorough up-to-date overview of all therapeutic approaches currently undergoing clinical trial. Read More

View Article and Full-Text PDF

Role of Semaphorins in Ischemic Stroke.

Front Mol Neurosci 2022 8;15:848506. Epub 2022 Mar 8.

Department of Neurology, Suzhou Ninth Hospital Affiliated to Soochow University, Suzhou, China.

Ischemic stroke is one of the major causes of neurological morbidity and mortality in the world. Although the management of ischemic stroke has been improved significantly, it still imposes a huge burden on the health and property. The integrity of the neurovascular unit (NVU) is closely related with the prognosis of ischemic stroke. Read More

View Article and Full-Text PDF

[Cardiovascular management of patients with chronic myeloid leukemia treated with BCR-ABL tyrosine kinase inhibitors: it is time for a shared management].

G Ital Cardiol (Rome) 2022 Apr;23(4):268-277

Dipartimento di Medicina, Chirurgia e Odontoiatria, Università degli Studi, Salerno - Dipartimento Cardio-Toraco-Vascolare, A.O.U. San Giovanni di Dio e Ruggi d'Aragona, Salerno.

Chronic myeloid leukemia is a rare myeloproliferative disease, characterized by a chromosomal translocation detected in 95% of cases, defined as "Philadelphia chromosome", encoding for the BCR-ABL fusion protein with continuous activation of the tyrosine kinase domain. Over the last 20 years, treatment has been revolutionized by the use of BCR-ABL tyrosine kinase inhibitors (TKI). Imatinib is the first TKI approved with a good cardiovascular safety profile, while some second-generation (nilotinib and dasatinib) and third-generation (ponatinib) drugs, developed to overcame drug resistance, can be associated with cardiovascular adverse events. Read More

View Article and Full-Text PDF

Stroke Associated with COVID-19 Vaccines.

J Stroke Cerebrovasc Dis 2022 Jun 4;31(6):106440. Epub 2022 Mar 4.

Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Research Unit of Clinical Physiology and Nuclear Medicine, Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark; Steno Diabetes Center Odense, Department of Clinical Research, University of Southern Denmark, Odense, Denmark; BRIDGE: Brain Research - Interdisciplinary Guided Excellence, Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Neuroscience Research Center, Guilan University of Medical Sciences, Rasht, Iran. Electronic address:

Objectives: Development of safe and effective vaccines against coronavirus disease 2019 (COVID-19) remains the cornerstone of controlling this pandemic. However, there are increasing reports of various types of stroke including ischemic stroke, and hemorrhagic stroke, as well as cerebral venous sinus thrombosis (CVST) after COVID-19 vaccination. This paper aims to review reports of stroke associated with COVID-19 vaccines and provide a coherent clinical picture of this condition. Read More

View Article and Full-Text PDF

Responder analysis for improvement in 6-min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency.

Eur J Heart Fail 2022 May 21;24(5):833-842. Epub 2022 Apr 21.

Department of Medicine, University of Mississippi, Jackson, MS, USA.

Aim: Improving functional capacity is a key goal in heart failure (HF). This pooled analysis of FAIR-HF and CONFIRM-HF assessed the likelihood of improvement or deterioration in 6-min walk test (6MWT) among iron-deficient patients with chronic HF with reduced ejection fraction (HFrEF) receiving ferric carboxymaltose (FCM).

Methods And Results: Data for 760 patients (FCM: n = 454; placebo: n = 306) were analysed. Read More

View Article and Full-Text PDF

Mesenchymal Stromal Cells in Ischemic Brain Injury.

Cells 2022 03 17;11(6). Epub 2022 Mar 17.

Center of Excellence for Aging and Brain Repair, University of South Florida Morsani College of Medicine, 12901 Bruce B Downs Blvd, Tampa, FL 33612, USA.

Ischemic brain injury represents a major cause of death worldwide with limited treatment options with a narrow therapeutic window. Accordingly, novel treatments that extend the treatment from the early neuroprotective stage to the late regenerative phase may accommodate a much larger number of stroke patients. To this end, stem cell-based regenerative therapies may address this unmet clinical need. Read More

View Article and Full-Text PDF